Pane wikiwiki
An estimated 1.3 million people acquired HIV in 2024, a 40.8 million were living with the virus at the end of that year (UNAIDS, 2025). Against a prevention …
He aha ka melittin a no ke aha e noʻonoʻo ʻia ai kahi peptide membrane-active e kūʻē i ka HIV-1?

ʻO Melittin he 26-koe cationic amphipathic peptide me ke kaʻina GIGAVLKVLTTGLPALISWIKRKRQQ-NH2 a me ke kaumaha molekala ma kahi o 2840 A (Nā palena i ka Immunology, 2024). ʻO kona ʻāpana N-terminal ka nui o ka hydrophobic aʻo ka ʻāina C-terminal he polar a cationic., no laila, ʻokiʻoki ka peptide i nā lipid bilayers a paʻi i loko o kahi amphipathic α-helix (PMC7224078, 2019).
Hoʻopuka kēlā ʻano hana i kahi hopena pili i ka noʻonoʻo: hoʻokomo i loko o ka membrane, oligomerization, a me ka hoʻokumu ʻana i ka pore e hoʻoheheʻe i nā ion a me nā mea intracellular. Ke hoʻopaʻapaʻa ʻia nei ka hoʻolālā pore pololei, akā, ʻo ka hopena o ka hana, ʻo ia ka hoʻopau ʻana i ka membrane (PMC7224078, 2019). No kahi maʻi virus i hoʻopaʻa ʻia, ʻO kahi peptide e uhaʻi i nā membrane he antiviral kūpono, a ʻekolu mau hana anti-retroviral i manaʻo ʻia: virolysis pololei o ka membrane viral, permeabilisation o ka envelopp, a me ka hoʻopau ʻana i ka hōʻike gene viral (PMC7224078, 2019).
ʻO ka pilikia ke koho. ʻAʻole koho ʻia ʻo Melittin no nā membrane viral; hoʻopau ia i nā membrane plasma mammalian, ʻoi aku ka erythrocytes (Nā palena i ka Immunology, 2024). Ua hōʻike ʻia kāna HC50 e kūʻē i ke koko ʻulaʻula kanaka 16.28 ± 0.17 µg/mL i kahi 2% pau ka hoʻomaha 24 hola, a ʻo kāna LC50 e kūʻē i nā cell dendritic kanaka makua ʻole 43.42 ± 0.86 µg/mL (Nā palena i ka Immunology, 2024).
ʻO ia ka pilikia loiloi holoʻokoʻa ma ka helu hoʻokahi. ʻAʻohe peptide ikaika o ka membrane me ka loaʻa ʻole o kahi kiʻi ʻawaʻawa o ka host-membrane, ʻO ia ke kumu e noʻonoʻo ʻia ai kekahi hana peptide membrane-active ma ka ratio, ʻaʻole ka waiwai antiviral wale nō.
ʻO ka moʻolelo unuhi no kēia papa peptide ke kaumaha. Ma mua o 3,000 Ua ʻike ʻia nā peptides antimicrobial, aka wale no 7 ua hiki i ka FDA aponoia, 5 o lakou membrane-active: gramicidin, daptomycin, oritavanc, televancin, a me ka colistin (PMC7168295, 2020). Loaʻa kēlā helu mai kahi loiloi hoʻokahi a pono e heluhelu ʻia ma ke ʻano he kiʻi kauoha-o-ka nui ma mua o ka helu attrition pololei..
He aha ka mea i hōʻike maoli ʻia e ka melittin-nanoparticle HIV-1 i loko o ka vitro?
Ua hōʻike ka noiʻi nanoparticle kumu i kahi IC50 o 2.4 µM a me kahi IC90 o 6.9 µM kū'ē iā CXCR4-tropic HIV-1 (kāʻili NLHX), a 3.6 µM a 11.4 µM e kūʻē i ka CCR5-tropic strain NLYU2 (PubMed 22954649, 2013). Ua hoʻohana ka assay i nā pūnaewele reporter TZM-bl e lawe ana i ka luciferase ma lalo o ka mea hoʻolaha HIV-1, me ka CD4 hiki ke hoʻoheheʻe ʻia e like me ka mana maikaʻi, nāna i hāʻawi i nā waiwai IC50 o 3.7 µg/mL kū'ē i ka CXCR4-tropic virus a 0.03 µg/mL e kūʻē i ka maʻi CCR5-tropic (PubMed 22954649, 2013).
ʻElua mau haʻalele ʻana e like me nā helu. Ka mua, ʻO ka loiloi antiviral e hoʻopili ana i kēia mau waiwai EC50 e hoʻopaʻa i ka CC50 a me ka helu koho koho ʻaʻole i hoʻoholo ʻia. (PMC7224078, 2019). ʻAʻole i paʻi ʻia ka papa kuhikuhi koho no kēia ʻāpana, no laila ʻo ka mea e haʻi ana i kahi puka aniani e helu ana i kahi mea a nā mea kākau i hana ʻole ai. Ka lua, ʻaʻohe lua keʻena hana i hoʻopuka hou i nā waiwai ma nā kumu i nānā ʻia ma aneʻi; ka 2.4 µM a 3.6 Hōʻike ʻia ka lua µM i ka uhi paʻi a me nā loiloi i lalo, aka, ua pau ia mau mea i keia pepa hookahi.
ʻO ka hoʻolālā pono'ī he kiko'ī a pono e haʻi pololei. ʻO ka mea lawe he inert perfluorooctyl bromide core me ka unilamellar lipid surfactant shell, a hoʻopaʻa melittin a hoʻokomo i loko o kēlā pūpū (PLoS KEKAHI, 2014). ʻO ka hui pū ʻana o ka lipid surfactant 98.9 mol% hua lecithin, 0.1 mol% DiI, a 1 mol% carboxy-PEG-DSPE, me kahi kiʻi lipid ma 2.0% w/v hui pū me ka perfluorooctyl bromide ma 20% w/v (PLoS KEKAHI, 2014).
Melittin manuahi ma lalo 2 ʻAʻole cytotoxic ʻo µM i nā pūnaewele reporter a maikaʻi loa e kūʻē i nā maʻi ʻelua, ʻoiai ua hōʻike ʻia ka nanoparticle me ka palekana e kūʻē i nā cell epithelial vaginal VK2 ma nā kau i hoʻāʻo ʻia (PubMed 22954649, 2013). ʻO ka manaʻo o nā mea kākau ponoʻī ua ʻike ʻia nā noiʻi e hiki mai ana e ʻimi i ka hiki prophylactic, ʻo ia ka papa inoa kūpono no ka hopena in vitro mua (PubMed 22954649, 2013).
Pehea ʻoe e hoʻoholo ai inā hoʻokaʻawale ʻia ka hopena antiviral mai ka pōʻino o ka host-membrane?
Hāʻawi ka haʻawina hoa i nā waiwai paʻa e hiki ai ke hoʻoholo. Loaʻa i ka melittin manuahi kahi VK2 vaginal epithelial cell viability IC50 o 1.3 µM, hōʻemi ʻia ka viability o nā cell vaginal ma 1 µM a ma luna, a hoemi i ka sperm motility a me ka viability maluna 2 µM, me 8 µM a ʻoi aku ka hoʻopau ʻana i nā mea ʻelua (PLoS KEKAHI, 2014).
E hoʻohālikelike i ka hana antiviral me ka hoʻohana ʻana i ka hoʻohālikelike hoʻohālikelike, kumu noonoo, ka lōʻihi o ka weheʻana a me nā pūnaewele pili. ʻAʻole hiki i nā waiwai mai nā haʻawina like ʻole ke hoʻokumu i kahi kuhikuhi koho koho a hōʻoia i ka hāʻule ʻole o ka peptide manuahi i kēlā me kēia pōʻaiapili.
Mea Hana Peptides Lepili Isotope Neoantigen Synthesis Hoʻololi ka hoʻohui ʻana o Nanoparticle i ka paepae ʻona, a ʻo kēlā hoʻololi ka ʻike maoli. ʻO nā nanoparticles Melittin he mea ʻawaʻawa i ka epithelium vaginal wale nō ma nā ʻano melittin like ʻole. 20 µM a i ʻole ma luna, a i ka sperm wale no ma 40 µM a i ʻole ma luna, he ʻelima hoʻemi i ka cytotoxicity pili i ka melittin manuahi (PLoS KEKAHI, 2014). ʻAʻole hōʻike ka pepa like ʻole i ka cytotoxicity i ka sperm a i ʻole ka epithelium vaginal ma kahi ʻano melittin kūlike o 10 µM, aia maluna o ka 2.4 µM a 3.6 µM mau waiwai antiviral.
He ʻokoʻa ka helu o nā kumu i kēlā pale, a he mea pono ke ike i ka like ole. ʻO ka 2013 ʻAʻole i hoʻopilikia ʻia ka hiki ʻana o VK2 ma kekahi ʻano o nā nanoparticles i hoʻouka ʻia melittin i hoʻāʻo ʻia., oiai ka 2014 hāʻawi ka pepa hoa i nā kiʻi kikoʻī o 10 Ua ʻae ʻia ʻo µM a 20 ʻO µM ke ʻano o ka ʻona mua (Neuropeptide Y Synthesis href="https://pubmed.ncbi.nlm.nih.gov/22954649/”>PubMed 22954649, 2013; PLoS KEKAHI, 2014). ʻO ka hope, ʻO ke kumu kikoʻī ʻoi aku ka mea e ʻōlelo ai, no ka mea, ʻoi aku ka laulā o "kekahi dosis" ma mua o ke kākoʻo ʻikepili.
ʻO ka hoʻololi ʻelima ʻaʻole ia he therapeutic index. He hoʻololi ia i hoʻokahi hoʻokolohua ma kekahi ʻano kelepona, a ʻo ka pepa hoʻokahi e ʻōlelo nei he pono ka hoʻāʻo hou ʻana no ka hoʻoholo ʻana i ka cytotoxicity i loko o kahi ʻōnaehana kumu hoʻohālike pili physiologically (PLoS KEKAHI, 2014). E mālama i ka huahelu ʻelima ma ke ʻano he hopena hoʻohua kūpono e hahai ai, ʻaʻole ma ke ʻano he palena palekana.
He aha nā ʻano formulation e wehewehe i ka huahana, ʻaʻole wale ka hoʻokolohua?
ʻO nā hiʻohiʻona e wehewehe i ka huahana nā mea a kahi regulator e noi ai iā ʻoe e hoʻokele, a ke kuhikuhi pololei nei ka FDA no nā huahana lāʻau lapaʻau liposome: ka nui o ka nui a me ka mahele nui, morphology a me ka lamellarity, hiki i ka zeta a i ʻole ka uku ʻupena, encapsulation pono, lāʻau kūʻokoʻa i hoʻokaʻawale ʻia mai ka lāʻau i hoʻopaʻa ʻia, a me ka ho'āʻo hoʻokuʻu in-vitro (FDA, 2018).
Ua kākau ʻia kēlā alakaʻi no nā liposomes, a ʻo ka mea lawe melittin he emulsion perfluorocarbon me kahi lipid monolayer, ʻaʻole he liposome bilayer (PMC2710241, 2008). ʻO ka hoʻohana ʻana ma aneʻi he ʻano hoʻohālikelike e manaʻo ka mea loiloi iā ʻoe e hōʻoia, ʻaʻole i koi ʻia. Paʻa mau ka papa inoa ʻano, no ka mea, hoʻololi kēlā me kēia mea i ke ʻano o ka huahana.
Ua ʻike ʻia ka nui a me ka uku o ka ʻili i ka wā o ka hoʻomohala ʻana: ʻo ke anawaena o ka ʻeleʻele ʻeleʻele 290 nm me ka loli ʻole ma hope o ka hoʻohui melittin (289.8 nm), a ua neʻe ka mana zeta mai −17.2 mV me ka melittin i +17.82 mV ma kahi ratio lipid-to-melittin o 30 (PMC2710241, 2008). He mau waiwai hoʻomohala kēlā, ʻaʻole kahi kikoʻī hoʻokuʻu, a me ka hōʻike ʻana iā lākou e like me ke kuhi hewa ʻana i ka mea i ana ʻia.
Hōʻike ka monolayer i ke kumu e ola ai ka mea lawe. Hoʻopaʻa ʻo Melittin i nā nanoparticles perfluorocarbon me kahi hoʻokaʻawale mau o kahi 3.27 nM, apono i ka α-helical hale me ka poepoe dichroism minima ma 208 a 220 nm, a kanu iā Trp-19 ma kahi kokoke i ke kikowaena perfluorocarbon (PMC2710241, 2008). Hōʻike ke kumu hoʻokahi i ke ʻano monolayer paʻa i ka microscopy electron ma hope o ka hoʻohui melittin, ʻokoʻa me nā liposomes bilayer e hōʻike ana i ka haunaele.
ʻOki ka nui i nā ʻaoʻao ʻelua, a ʻaʻole ʻae nā kumu i ke ala hea. Hoʻopaʻapaʻa ka pepa hoa i ka 250 i 300 Hiki i ke anawaena nm ke pale i ke komo ʻana o ka pale epithelial vaginal a no laila e hōʻemi i ka absorption systemic (PLoS KEKAHI, 2014), ʻoiai ʻo ka loiloi ʻōnaehana hoʻopuka e hōʻike ana i ka nui like ʻole i kūpono i ka diffusion a me ka lawe ʻana i nā kelepona ma ka pūnaewele. (PMC8773652, 2022). ʻO ke ana hoʻokahi he pale i ka heluhelu hoʻokahi a me ke keʻakeʻa i kekahi, a e hoʻoholo ka hui huahana i ka mea no ke ala i manaʻo ʻia.
No ke aha i ʻike ʻole ai kahi hōʻike hoʻopaʻapaʻa-cell i ka hana mucosal a i ʻole ka hana hou ʻana?
ʻO ka hoʻāʻo ʻana o ka mea hoʻolaha pūnaewele e ana maikaʻi i hoʻokahi mea a ʻaʻole loa kekahi mau mea. Hoʻohālikelike ka ʻōnaehana TZM-bl i ka maʻi ma o ka luminescence a wikiwiki a kūpono hoʻi, akā, ua ʻōlelo ka loiloi preclinical microbicide e hōʻoia mau ʻia ka maikaʻi i nā cell mua, ʻoi aku ka nui o nā cell CD4 T, ʻo ia nā pahuhopu mua o ka maʻi HIV (PMC4818646, 2015).
ʻO ke koho Strain ka lua lua. Ua hoʻāʻo ʻia ka melittin nanoparticle e kūʻē iā NLHX a me NLYU2, nā kānana ʻelua i hoʻololi ʻia e ka laboratory (PubMed 22954649, 2013). Hōʻike ka loiloi like i ka hoʻohana ʻana o CCR5-tropic transmitted/founder strains, ʻaʻole wale i nā kānana i hoʻololi ʻia e ka laboratory, He mea koʻikoʻi no ka mea he mau hiʻohiʻona kūʻokoʻa nā maʻi hoʻoili/hoʻokumu (PMC4818646, 2015). Heluhelu pu, ʻaʻole i hoʻāʻo ʻia ka ʻāpana kūʻē i ka papa kānana i manaʻo ʻia e ke kahua he mea pili loa i ka hoʻoili ʻana.
ʻO ka plasma Seminal ke kolu o ka hakahaka, a kau pololei ia ma luna o ka virucide hoʻopaʻi ʻia. Ua hoʻonui ka Seminal plasma i ka IC50 o nā mea hoʻopaneʻe e kū'ē i ka transcriptase, hoʻohui, a protease e 8 i 21 pelu, ʻoiai ka CCR5 inhibitor maraviroc, ka mea e hoʻopaʻa nei i kahi mea kelepona, noho ikaika (PMC4818646, 2015). Hōʻike ʻia nā nanoparticles Melittin e hopu a hoʻopau i ka virion, ʻo ia ka mea e hoʻopaʻa ʻia ai lākou, ʻAʻohe kumu i loiloi ʻia ma ʻaneʻi e hōʻike ana i ka hana melittin i mua o ka plasma seminal.
Hoʻomaopopo pū ka loiloi e koi ana nā haʻawina explant i nā dosis viral kiʻekiʻe loa e hoʻokumu i ka maʻi a no laila ʻaʻole kūpono no ka haʻahaʻa haʻahaʻa., inocula pili kino, a ʻo ka mea ʻawaʻawa i hoʻokomo ʻia e ka moho hiki ke kuhi hewa no ka hana antiviral (PMC4818646, 2015). ʻO kēlā helu hope ka pahele no nā mea hana membrane: ʻO kahi peptide e pepehi ana i nā pūnaewele ke nānā aku e like me ka peptide e hoʻōki i ka maʻi.
Hoʻohui hou ʻia ka ʻike mucosal i kahi papa hoʻoponopono i hoʻopā ʻole ʻia ka hoʻokolohua hoʻokahi. ʻIke ʻia nā huahana pale topical me ka hoʻopaʻa pinepine ʻana i nā mea make ma nā ʻano ʻelua, nā haʻawina hoʻohua a me nā mea ʻawaʻawa hānau, a me ka ho'āʻo hoʻonanea kūloko (FDA, Kūʻai nui nā mea hana Peptide 2005), a ʻo ke alakaʻi ʻana i ka microbicide vaginal e ʻōlelo ana i ka loiloi ʻana i ka mumū cervicovaginal a me ka hoʻopau ʻana o ka epithelial. (FDA, 2014). ʻAʻole ʻōlelo kahi heluhelu luciferase 48-hola e pili ana i kekahi o ia mea.
He aha ka hōʻike a me nā moʻolelo e pono ai ka mea loiloi?

E hoʻomaka me ke kāʻei kikoʻī, no ka mea, he maʻalahi ka hewa. No kahi peptide i hoʻohui ʻia i ke kemika, ʻo ke kumu nui ʻo ICH Q6A, ʻoiai ʻo ICH Q6B e hoʻokaʻawale loa i nā peptides synthetic (I, 1999). E hōʻoia i ka ʻōlelo kikoʻī Q6A e kūʻē i ka kikokikona o kēia manawa ma mua o ka waiho ʻana, no ka mea, ʻo ka ʻōlelo pili ka ʻāpana loiloi e nānā mua.
Hoʻolālā i nā haʻawina kūpaʻa no ka hoʻolālā i manaʻo ʻia, ipu, alahele a me ke koi mālama. ʻAʻole ʻokoʻa nā hiʻohiʻona o ke keʻena ICH maʻamau i nā kūlana i koi ʻia no kahi emulsion perfluorocarbon topical. Hōʻike i ka pono o ka peptide, peptide manuahi a pili, nā waiwai a me nā hana i loko o ka manawa kūpono.
ʻAʻohe kumu i loiloi ʻia ma ʻaneʻi e hōʻike ana i ke kūpaʻa nanoparticle melittin ma lalo o kekahi o ia mau kūlana. Hōʻike ka pepa hoa i ka nui a me ka zeta hiki ke hoʻokūpaʻa i ka pH vaginal no ka liʻiliʻi o ʻekolu lā (PLoS KEKAHI, 2014), ʻaʻole ia he kūlana mālama ICH. ʻO kēlā āpau ka ʻokoʻa ma waena o kahi hoʻolālā e ola ana i kahi hoʻokolohua a me kekahi me kahi ola paʻa.
No ka injectable, Ua kapa ʻia nā manaʻo sterility a me endotoxin i nā mokuna: USP <71> Nā ho'āʻo maʻemaʻe, USP <85> Ho'āʻo Endotoxins Bacterial, a me USP <788> Mea ʻāpana ʻāpana i loko o nā Injections (USP, kēia manawa). Noho nā palena helu ma ka paukū mokuna a pono e kuhikuhi ʻia mai laila mai ma mua o ka hōʻuluʻulu manaʻo.
Hoʻohui ka FDA liposome alakaʻi i kahi manaʻolana hana i maʻalahi ke nalo: pono e hōʻike ʻia ka sterility a me ka nele o nā pyrogens a i ʻole endotoxins bacteria, ʻO ka hoʻomaʻemaʻe pono huahana a me nā ʻano sterilization pono e hōʻike i ka hana sterilizing filters me ka ʻole o ka hoʻopaʻapaʻa ʻana i ka pono o ka ʻāpana., a me ka hoʻomalu endotoxin pono e kamaʻilio ʻia ma ke kaʻina hana ma mua o ka hoʻāʻo ʻana i ka huahana pau (FDA, 2018).
Pono ka pūʻolo noiʻi e hoʻopili i ka ʻike, maʻiʻo peptide, manuahi me ka peptide pili, ka nui a me ka puunaue ana, uku ʻili, hoʻokuʻu a me nā mana olaola pili i ka hailona i hoʻāʻo ʻia. Hoʻohui i ka microbiological, endotoxin a me nā ʻāpana ʻāpana e like me ke ala, ke kahua a me ka hoʻokumu ʻana ma mua o ka lawe ʻana i nā koi injectable āpau i kahi prototype kumuhana. Mea Hana Hana Peptide
He aha nā hōʻike e nalo nei ma mua o ka ʻae ʻia ʻana o nā koi lapaʻau a ʻoihana paha?

ʻO ka mea i haʻi ʻia 2024 ʻAʻole i hoʻokumu ka loiloi i ka pono lapaʻau a i ʻole ka palekana o ka melittin no ka pale ʻana i ka maʻi HIV. He ʻōlelo hōʻike hōʻike kēia, ʻaʻole kahi loiloi hoʻopaʻa inoa piha o kēlā me kēia melittin formulation a i ʻole hōʻailona.
ʻAʻohe kumu i nānā ʻia ma ʻaneʻi e hōʻike ana i kahi hopena maikaʻi i loko o ka vivo no kahi melittin nanoparticle vaginal virucide. Hōʻike ka pepa hoa ʻo ka pahuhopu lōʻihi he kahua hoʻokumu i ka gel vaginal a pono nā hoʻokolohua hou aʻe o ka palekana a me ka maikaʻi i nā ʻano holoholona e pili pono ana i ke kaiapuni vaginal. (PLoS KEKAHI, 2014). Kāhea ka pepa mua i kāna ʻikepili he hōʻoia mua o ka manaʻo a ʻōlelo ʻia he pono nā noiʻi e hiki mai ana (PubMed 22954649, 2013).
ʻAʻole hoʻoholo ʻia ka mīkini ma ke ʻano e hoʻololi ai i kāu mea e ana. ʻO ka 2013 ʻO ka abstract hoʻonohonoho i ka ʻāpana e like me ka hopu ʻana a me ka hoʻopau ʻana i ka maʻi maʻi, ʻOiai ke hōʻike nei ka loiloi antiviral i ka hōʻike kumulative e hōʻike ana i ka hopena anti-HIV i hilinaʻi ʻia e ka hopena ma ke kāohi ʻana i ka palapala HIV a me ka hoʻohaʻahaʻa ʻana i nā huahana gene viral ma mua o ka lysis o nā membrane cellular a viral. (PubMed 22954649, 2013; PMC7224078, 2019). He mau heluhelu hoʻokūkū kēia, ʻaʻole i hoʻopaʻa ʻia, a ke hōʻike nei lākou i nā hoʻokolohua like ʻole a me nā ʻano hana hemahema ʻē aʻe.
Pono e kapa ʻia ʻelua mau āwaha. ʻO ka hoʻouka ʻana i ka lāʻau i hōʻike ʻia no nā mea lawe melittin e noho ana ma ka helu pākēneka helu hoʻokahi, me hoʻokahi hoʻolālā PLGA e pili ana 90% hoʻouka pono a 6 i 7% maʻi lāʻau ma hope o ka hui ʻana o ka ion (PMC8773652, 2022); ʻO kēlā mau waiwai no kēlā mea lawe kikoʻī a ʻaʻole pono e hoʻohui ʻia i hoʻokahi pae. A ʻike ʻia nā helu hoʻonui hapalua o ka plasma i ka loiloi, ʻaʻole i loko o kekahi pepa hoʻokumu mua i nānā ʻia ma aneʻi (PMC8773652, 2022). Nmm Peptide Synthesis
ʻO ke alapiʻi hōʻike, i mea e: replication kūʻokoʻa o nā waiwai IC50, he papa kuhikuhi koho i paʻi ʻia, hana e kū'ē i nā mea i hoʻouna ʻia/hoʻokumu i nā pūnae CD4 T mua, ka hana i mua o ka plasma seminal a me ka wai cervicovaginal, hoʻopā hou ʻia ka mucosal i loko o ʻelua mau ʻano, ICH format paʻa ʻikepili, a me ka hopena in vivo efficacy. A hiki i ka piha ʻana o kēlā mau pae, ʻO ka wehewehe pono o ka melittin nanoparticles a me ka HIV-1 he hōʻailona in vitro hoʻohiwahiwa me kahi mea lawe maikaʻi ʻia a ʻaʻohe ala lapaʻau i hōʻike ʻia..
Nīnau pinepine
Ua hoʻāʻo ʻia nā nanoparticles melittin i nā kānaka?
ʻO nā haʻawina nanoparticle HIV-1 i haʻi ʻia he preclinical a ʻaʻole i hoʻokumu i ka pono lapaʻau a palekana paha. ʻO ka 2024 Ua hoʻopaʻa ʻia ka moʻolelo o ka loiloi o nā hōʻike kanaka; ʻAʻole hiki iā ia ke hoʻopaʻa pono ʻaʻohe haʻawina melittin kanaka i ʻOkakopa 2026. ʻAʻole hana kēia ʻatikala i kahi koi hoʻāʻo lapaʻau piha i kēia manawa.
Loaʻa i ka 2013 ʻO ka hopena melittin nanoparticle HIV-1 i hana hou ʻia?
ʻAʻole ma nā kumu i nānā ʻia ma aneʻi. ʻO ka hana cytolytic-nanoparticle kumu e kū nei ma ke ʻano he hōʻike hoʻokahi, a ʻaʻohe pūʻulu kūʻokoʻa e hōʻoia i ka ʻāpana like e kūʻē i ka HIV-1 i ʻike ʻia ma kēia pūʻulu hōʻike. He mea nui ia no ka nui o ke kaumaha o ka hopena: ʻO ka ʻike in vitro hoʻokahi kahi hoʻomaka no ka melittin nanoparticles a me ka noiʻi HIV-1, ʻaʻole he hopena paʻa.
He aha ka helu koho o nā nanoparticles melittin?
ʻAʻole nā kumu i hōʻuluʻulu ʻia ma ʻaneʻi e hoʻokumu i kahi papa kuhikuhi koho hoʻohālikelike pololei no ka huahana i manaʻo ʻia. E helu i hoʻokahi wale nō mai nā wahi hoʻopau antiviral a me cytotoxicity, me ka maopopo ole a me na kulana hoao i oleloia.
He palekana anei ka melittin nanoparticles no ka hoʻohana ʻana i ka wahine?
ʻO ka pane ʻoiaʻiʻo ʻaʻole i hōʻike ʻia e kekahi. Ua ʻae ʻia ka melittin pili i ka nanoparticle a hiki i 20 µM i ʻelua ʻano kelepona, he ʻelima mau hoʻomaikaʻi ma mua o ka melittin manuahi (PLoS KEKAHI, 2014). ʻO ia kahi hoʻohālikelike cytotoxicity i nā cell moʻomeheu, a ʻo ka pepa ponoʻī e kāhea i ka hoʻāʻo ʻana i kahi kumu hoʻohālike pili physiologically. ʻAʻohe papa hou, Loaʻa ka ʻikepili kūloko a i ʻole in vivo.
Pehea e hoʻohālikelike ai nā nanoparticles melittin me nā antiretrovirals i ʻae ʻia?
ʻAʻole lākou i hoʻohālikelike ʻia. Ma ka hoʻopaʻa haʻawina HIV-1 mua, he CD4 hiki ke hoʻomalu maikaʻi, ʻaʻole he lāʻau i ʻae ʻia (PubMed, 2013). ʻAʻohe poʻo-a-poʻo e kūʻē i kekahi lāʻau antiretroviral i laikini ʻia ma kēia pūʻulu kumu, no laila, ʻaʻole hiki ke kiʻi ʻia kahi kūlana mana e kūʻē i ka lāʻau o kēia manawa mai ka ʻikepili i loaʻa.
Hiki i kahi mea hoʻolako peptide ke kākoʻo i kēia ʻano hana?
ʻAe, i loko o nā palena i wehewehe ʻia. Hiki i kahi hoa hana synthesis ke hāʻawi i ka hoʻolālā ʻana a me ka hoʻololi, ka maʻemaʻe a me ka palapala ʻike, ka lawelawe ʻana i ka sterile a me ka endotoxin haʻahaʻa, a me ka hoʻomau ʻana mai ka hana hoʻokolohua liʻiliʻi a hiki i ka nui. ʻO ka mea hiki ʻole i ka mea hoʻolako ke hoʻokumu i ka pono antiviral a i ʻole ka palekana mucosal; mau nīnau no ka hana hoʻokolohua i hōʻike ʻia ma luna.
Ka hopena
He mea maoli ka hopena nanoparticle melittin, kikoʻī, a haiki. Ua lawe ʻia ka melittin kahi ʻāpana perfluorocarbon me kahi monolayer lipid i nā waiwai IC50 o 2.4 µM a 3.6 µM e kūʻē i ʻelua mau ʻano HIV-1 i hoʻololi ʻia i loko o kahi hōʻike pūnaewele hōʻike, a ua hoʻololi ka hoʻohālikelike like i ka paepae cytotoxicity melittin i ʻelima mau manawa i ka haʻawina hoa (PubMed 22954649, 2013; PLoS KEKAHI, 2014).
ʻO ka mea i kākoʻo ʻole ʻia e nā hōʻike he koi ʻē aʻe ma mua o kēlā. ʻAʻohe papa kuhikuhi koho i paʻi ʻia, ʻaʻohe kope kūʻokoʻa, ʻaʻohe ʻikepili i hoʻouna ʻia/hoʻokumu, ʻaʻohe ʻikepili plasma seminal, ʻaʻohe paʻa ICH-format, ʻaʻohe in vivo efficacy, ʻaʻohe hoʻokolokolo kanaka. ʻO nā hōʻike unuhi no nā peptides antiviral o kēia papa he lahilahi no ke kumu, a me ka 7 ʻAe ʻia ʻo FDA ma mua o 3,000 ʻO nā peptides i ʻike ʻia ke ʻano o ia moʻolelo (PMC7168295, 2020).
ʻO ka lawe ʻana maʻamau no kēlā me kēia e loiloi ana i ka hopena peptide hana membrane ʻo ia ka lula waiwai paʻa. Mai ʻae ʻoe i kahi kiʻi ikaika antiviral me ka ʻole o ka paepae ʻawaʻawa host-membrane i ana ʻia ma nā ʻāpana like ma ke ʻano cell pili., a ʻaʻole loa e ʻae i ka hoʻopiʻi ʻana me ka ʻole o ka ʻikepili hiʻona e wehewehe i ka huahana: nui, uku, manuahi me ka peptide pili, hoʻokuʻu, sterility, a me ka endotoxin. E noi i kēlā ho'āʻo i ka hopena aʻe āu i heluhelu ai, me keia, a noho ka hōʻailona in vitro ma kona wahi kūpono.
